Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.8 USD | +9.38% | +9.38% | +18.64% |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
- According to Refinitiv, the company's ESG score for its industry is poor.
Strengths
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- The opinion of analysts covering the stock has improved over the past four months.
Weaknesses
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+18.64% | 180M | - | C- | |
+1.10% | 106B | B+ | ||
+9.29% | 103B | B+ | ||
-3.00% | 21.44B | B | ||
-11.89% | 22.11B | B+ | ||
-26.59% | 20.99B | A- | ||
-5.20% | 19.44B | A- | ||
-6.58% | 17.6B | B | ||
+5.83% | 13.88B | C+ | ||
+7.46% | 11.75B | D |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock
- Equities
- Stock GlycoMimetics, Inc. - Nasdaq
- Ratings GlycoMimetics, Inc.